AlphaCore Pharma is developing ACP-501 (rhLCAT) for the treatment of the orphan disease familial LCAT deficiency (FLD) and for the acute treatment of atherosclerosis.
Contact Us
AlphaCore Pharma
333 Parkland Plaza
Suite 5
Ann Arbor, MI 48103
734-527-9137 – Main Office
734-418-2531 – Fax